Nijiro Nohata
Overview
Explore the profile of Nijiro Nohata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oridate N, Takahashi S, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1825-1839.
PMID: 39382718
Background: Previously reported results from phase III KEYNOTE-048 demonstrated similar or improved overall survival (OS) with pembrolizumab or pembrolizumab-chemotherapy versus cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck...
2.
Venzel R, Campos M, de Oliveira L, Dan Lins R, Siena A, Mesquita K, et al.
Crit Rev Oncol Hematol
. 2023 Apr;
186:103988.
PMID: 37086955
Traditional therapeutic approaches for malignant melanoma, have proved to be limited and/or ineffective, especially with respect to their role in improving patient survival and tumor recurrence. In this regard, immunotherapy...
3.
Aersilan A, Hashimoto N, Yamagata K, Yokoyama M, Nakayama A, Shi X, et al.
Sci Rep
. 2022 Nov;
12(1):18443.
PMID: 36323841
The microRNA (miR) miR-874, a potential tumour suppressor, causes cell death via target gene suppression in various cancer types. Mevalonate pathway inhibition also causes cell death in breast cancer. However,...
4.
Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, et al.
Int J Clin Oncol
. 2022 Oct;
27(12):1805-1817.
PMID: 36264378
Background: Here, we report the results of the Japanese subgroup of the phase 3 KEYNOTE-048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil (pembrolizumab-chemotherapy), or cetuximab plus platinum and...
5.
Saito T, Asai S, Tanaka N, Nohata N, Minemura C, Koma A, et al.
Int J Mol Sci
. 2022 Aug;
23(16).
PMID: 36012427
Advanced-stage oral squamous cell carcinoma (OSCC) patients are treated with combination therapies, such as surgery, radiation, chemotherapy, and immunotherapy. However, OSCC cells acquire resistance to these treatments, resulting in local...
6.
Rigiracciolo D, Nohata N, Lappano R, Cirillo F, Talia M, Adame-Garcia S, et al.
J Exp Clin Cancer Res
. 2022 Jun;
41(1):193.
PMID: 35655319
Background: Understanding the intricate signaling network involved in triple-negative breast cancer (TNBC) represents a challenge for developing novel therapeutic approaches. Here, we aim to provide novel mechanistic insights on the...
7.
Asai S, Koma A, Nohata N, Kinoshita T, Kikkawa N, Kato M, et al.
Biomedicines
. 2022 Mar;
10(3).
PMID: 35327465
Based on our original RNA sequence-based microRNA (miRNA) signatures of head and neck squamous cell carcinoma (HNSCC), it was revealed that the expression levels of miR-1-3p, miR-206, miR-133a-3p, and miR-133b...
8.
Misono S, Mizuno K, Suetsugu T, Tanigawa K, Nohata N, Uchida A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33801812
Small cell lung cancer (SCLC) is a highly aggressive cancer, and patients who become refractory to first-line treatment have a poor prognosis. The development of effective treatment regimens is urgently...
9.
Rigiracciolo D, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, et al.
Cells
. 2020 Dec;
9(12).
PMID: 33291355
The authors wish to make the following changes to their paper [...].
10.
Shinden Y, Hirashima T, Nohata N, Toda H, Okada R, Asai S, et al.
J Hum Genet
. 2020 Nov;
66(5):519-534.
PMID: 33177704
Our recent research has revealed that passenger strands of certain microRNAs (miRNAs) function as tumor-suppressive miRNAs in cancer cells, e.g., miR-101-5p, miR-143-5p, miR-144-5p, miR-145-3p, and miR-150-3p. Thus, they are important...